Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delaying surgery beyond six weeks after systemic therapy reduces postoperative morbidity without evidence of impaired oncologic outcomes in colorectal liver metastases.

BMC cancer·2026
Same author

Pancreatic Cancer Frequently Infiltrates the TRIANGLE Compartment: A Surgical Option to Prevent Local Recurrence.

Annals of surgery open : perspectives of surgical history, education, and clinical approaches·2026
Same author

Multiphasic Evidential Decision-Making Matrix (MedMax) for Intrahepatic Cholangiocarcinoma: A Single-Center Validation Study.

Cancers·2026
Same author

Textbook outcome can be reached in the learning curve for hybrid robot-assisted esophagectomy-experience from a German high-volume center.

Journal of robotic surgery·2026
Same author

RadiSurg-Need of Implementation of an Interdisciplinary Surgical-Based Radiological Anatomy Course.

Medical science educator·2026
Same author

The Role of Circulating Tumor DNA in Surgical Management of Pancreatic Cancer: Systematic Review and Meta-analysis.

Annals of surgery·2026

Related Experiment Video

Updated: Jul 11, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Sirolimus in renal transplantation.

Christian Morath1, Wolfgang Arns, Vedat Schwenger

  • 1Department of Nephrology, University of Heidelberg, Im Neuenheimer Feld 162, 69120 Heidelberg, Germany. christian.morath@med.uni-heidelberg.de

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|November 29, 2007
PubMed
Summary

Mammalian target of rapamycin inhibitors like sirolimus offer a promising alternative for renal transplant immunosuppression. They reduce side effects like nephrotoxicity and hypertension, improving long-term graft survival.

More Related Videos

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Related Experiment Videos

Last Updated: Jul 11, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Renal transplantation outcomes are limited by chronic allograft nephropathy and patient mortality.
  • Calcineurin inhibitor toxicity, hypertension, cardiovascular events, infections, and malignancy contribute to allograft loss.
  • Graft half-life has stagnated despite reduced acute rejection rates.

Purpose of the Study:

  • To review the current literature on mammalian target of rapamycin (mTOR) inhibitors in renal transplantation.
  • To highlight the potential of mTOR inhibitors as an alternative maintenance immunosuppression strategy.
  • To focus specifically on the role and benefits of sirolimus.

Main Methods:

  • Literature review of studies on mTOR inhibitors in renal transplantation.
  • Analysis of efficacy and safety profiles compared to calcineurin inhibitors.
  • Focus on sirolimus and its unique characteristics.

Main Results:

  • Mammalian target of rapamycin inhibitors have a different mechanism of action and side effect profile compared to calcineurin inhibitors.
  • mTOR inhibitors demonstrate lower nephrotoxicity, reduced hypertension, and less neoplastic potential.
  • These agents offer a promising alternative for maintenance immunosuppression.

Conclusions:

  • Mammalian target of rapamycin inhibitors represent a significant advancement in renal transplant immunosuppression.
  • Sirolimus, in particular, shows potential for improving long-term graft survival by mitigating key adverse effects.
  • Further research and clinical application of mTOR inhibitors are warranted.